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Abstract
Purpose Inconsistent reporting of outcomes in clinical
trials of patients with non-specific low back pain (NSLBP)
hinders comparison of findings and the reliability of sys-
tematic reviews. A core outcome set (COS) can address
this issue as it defines a minimum set of outcomes that
should be reported in all clinical trials. In 1998, Deyo et al.
recommended a standardized set of outcomes for LBP
clinical research. The aim of this study was to update these
recommendations by determining which outcome domains
should be included in a COS for clinical trials in NSLBP.
Methods An International Steering Committee estab-
lished the methodology to develop this COS. The
OMERACT Filter 2.0 framework was used to draw a list of
potential core domains that were presented in a Delphi
study. Researchers, care providers and patients were in-
vited to participate in three Delphi rounds and were asked
to judge which domains were core. A priori criteria for
consensus were established before each round and were
analysed together with arguments provided by panellists on
importance, overlap, aggregation and/or addition of po-
tential core domains. The Steering Committee discussed
the final results and made final decisions.
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Results A set of 280 experts was invited to participate in
the Delphi; response rates in the three rounds were 52, 50
and 45 %. Of 41 potential core domains presented in the
first round, 13 had sufficient support to be presented for
rating in the third round. Overall consensus was reached for
the inclusion of three domains in this COS: ‘physical
functioning’, ‘pain intensity’ and ‘health-related quality of
life’. Consensus on ‘physical functioning’ and ‘pain in-
tensity’ was consistent across all stakeholders, ‘health-re-
lated quality of life’ was not supported by the patients, and
all the other domains were not supported by two or more
groups of stakeholders. Weighting all possible argumen-
tations, the Steering Committee decided to include in the
COS the three domains that reached overall consensus and
the domain ‘number of deaths’.
Conclusions The following outcome domains were in-
cluded in this updated COS: ‘physical functioning’, ‘pain
intensity’, ‘health-related quality of life’ and ‘number of
deaths’. The next step for the development of this COS will
be to determine which measurement instruments best
measure these domains.
Keywords Core outcome set  Domains  Clinical trials 
Non-specific low back pain
Introduction
The Global Burden of Disease study has highlighted that
low back pain (LBP) is the leading global contributor to
years lived with disability and the sixth global contributor
to disability-adjusted life years [1, 2]. The global preva-
lence of activity-limiting LBP was recently estimated to be
approximately 39 % for lifetime prevalence and 18 % for
point-prevalence [3]. Only a small proportion of people
experiencing LBP seek health care but these account for
high costs that represent an important burden to society [4,
5]. The large majority of patients with LBP are labelled as
having non-specific LBP (NSLBP) because no underlying
pathology or cause can be found [6–8]. A wide range of
health interventions exists for patients with NSLBP and
related clinical trials are often summarized in systematic
reviews [9, 10]. However, authors of these reviews report
that outcomes are inconsistently measured and reported
across trials [11–13]. This inconsistency may limit the
comparison of findings among trials and hinder statistical
pooling [14]. In addition, inconsistent reporting can be due
to selective reporting bias (e.g. reporting only favourable
outcomes in a publication), which may strongly affect the
conclusions of systematic reviews [15].
The development and use of core outcome sets (COS)
for specific health conditions has been suggested to reduce
inconsistency in outcomes measured and reported across
clinical trials [14]. A COS represents an agreed set of
outcomes that should be measured and reported, as a
minimum, in all clinical trials for specific health conditions
[16]. Such a set does not restrict measurement or the choice
of the primary outcome, but mandates collection and re-
porting of the COS alongside the outcomes of interest [16].
A COS thus creates a minimum standard of outcomes re-
ported, reducing the risk of selective reporting bias and
increasing the validity and statistical power of meta-ana-
lyses [17].
The recently launched Core Outcome Measures in Ef-
fectiveness Trials (COMET) initiative fosters method-
ological research and provides methodological guidance on
the development of a COS [16]. The expertise accumulated
by the Outcome Measures in Rheumatology (OMERACT)
initiative is also a fundamental guidance in COS develop-
ment [18]. A stepwise approach is suggested by both ini-
tiatives: first, the core outcome domains should be selected
(i.e. ‘what’ to measure), and then the measurement in-
struments for each domain (i.e. ‘how’ to measure) [16, 19].
In the field of LBP, recommendations for standardized
reporting of outcome measurement instruments in clinical
studies were formulated at an expert panel discussion held
at the 1997 International Forum on LBP in Primary Care
(The Hague, The Netherlands) [20]. Specific recommen-
dations were made for five outcome domains (i.e. ‘pain
symptoms’, ‘back-related function’, ‘generic well-being’,
‘disability social role’ and ‘satisfaction with care’) [20, 21].
A workshop discussion among LBP researchers during the
2012 International LBP Forum (Odense, Denmark) agreed
on the need of updating the existing recommendations [22].
This was motivated by recent advances in understanding of
construct development and measurement properties that
stress the need to explore whether relevant domains are
missing and to critically appraise recommended instru-
ments [22]. Deyo et al. [20] proposed also a parsimonious
set of six questions covering the five domains suggested for
measurement in LBP clinical research. These questions
were extracted from existing questionnaires and were
proposed as the minimum to be used in a wide variety of
settings, including routine clinical care [20]. This brief set
was labelled as ‘Core Outcome Measures Index’ (COMI)
by other investigators who assessed its measurement
properties and feasibility of implementation [23, 24].
However, it is out of the scope of this study to update the
set of questions included in the COMI for LBP.
The aim of this study is to update the existing stan-
dardized set of outcome domains and measurement in-
struments recommended for LBP [20, 21], through the
development of a COS. This COS is intended for the
measurement of efficacy or effectiveness of health inter-
ventions assessed in all clinical trials for patients with
NSLBP. We defined NSLBP as ‘‘low back pain not
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attributable to a recognizable, known specific pathology
(e.g. infection, tumour, fracture, axial spondyloarthritis)’’
[25]. The first step in the development of this COS and
focus of this manuscript was to perform a Delphi study to
reach international consensus on core outcome domains.
Methods
A detailed description of the methods of this Delphi study
is presented elsewhere [26]. An International Steering
Committee with members from four continents, including
researchers, care providers and patients’ representatives,
worked on the development of this COS. The day-to-day
conduction of the study was performed by a project team
of four people (AC, CT, MB, RO) working at the same
institution (VU University/VU Medical Center, Amster-
dam) who designed and addressed key aspects of the study.
The other members of the Committee were regularly con-
sulted by e-mail regarding critical decisions.
The Steering Committee decided to involve four groups
of stakeholders in the Delphi study: health care researchers,
health care providers, professionals working both as re-
searchers and providers, and patients with NSLBP. Pro-
fessionals from many fields of clinical research relevant for
NSLBP (e.g. orthopaedics, physiotherapy, epidemiology,
psychology, rheumatology, rehabilitation medicine) were
involved. Patients are judged to be essential in developing
COSs as they can bring the perspective of those living with
a health condition [16, 18]. Previous COS efforts involving
patients or the public identified core outcome domains that
were not previously identified by other stakeholders
[27–29].
The main advantages of a Delphi method include the
involvement of informed individuals, anonymity of re-
sponses that reduces influence of prominent personalities,
and the possibility for Delphi panellists to reconsider their
views based on feedback reports of previous rounds [30,
31]. As this project did not involve experiments with pa-
tients or study subjects, according to the Dutch Medical
Research in Human Subjects Act (WMO), it was exempt
from ethical approval. All patients involved were asked for
their consent prior to participation and all procedures were
conducted according to the Declaration of Helsinki.
Selection of panellists
A list of health care researchers who had extensively
published on LBP over the last 10 years (2003–2013) was
made by one reviewer (AC) through a structured search in
Web of Science (accessed October 7, 2013) and PubMed
[26]. Other researchers and health care providers were
added to this list through convenience sampling. Patients
were recruited through the Steering Committee, seeking
people who sought care for a present or past episode of
NSLBP and had a fluent understanding of written English.
When patients willing to participate were identified, they
were contacted by email, given further information on the
study and asked for consent to participate. Patients agree-
ing to participate were sent an information document giv-
ing simplified explanations of the terminology used in the
study. Members of the Committee were also selected to
participate in the Delphi so that they could express their
vote on core domains. The final list of potential panellists
was managed by the project team and names in the list
remained blinded to all those selected for participation.
Generation of a list of potential core domains
The Steering Committee took responsibility for drawing a
list of potential core domains that was used in the Delphi
study. This list resulted from a search of outcome domains
measured in clinical trials included in five recent system-
atic reviews [12, 13, 32, 33] (one of which not published
yet) with addition of the (sub) domains included in the
comprehensive International Classification of Functioning
(ICF) core set for LBP [34], and in a conceptual model
developed to characterize the burden of LBP [35]. This
conceptual model and the ICF core set were adopted to
account for the patients’ perspective in this early phase.
The model on the burden of LBP was developed by asking
different stakeholders (including patients) which aspects of
health were the most relevant to them [35]; the compre-
hensive ICF core set was shown to cover all health issues
identified by patients with LBP [36]. The OMERACT
Filter 2.0 framework was used to structure the list of po-
tential core domains, subdividing it into four core areas that
encompass the complete content of what is potentially
measurable in a clinical trial (‘‘Appendix I’’) [19]. To de-
termine wording and definitions of the potential core do-
mains, terminology used in existing health frameworks or
COSs were consulted: ICF [37], Patient Reported Out-
comes Measurement Information System (PROMIS) [38],
Wilson and Cleary Model [39] and IMMPACT [40, 41].
Delphi procedure
Three Delphi rounds, including open- and close-ended
questions, were used to reach consensus on core outcome
domains. Individuals not participating in one round, and
who did not explicitly express their desire to opt-out, were
invited to each subsequent round. The Delphi study was
conducted using SurveyMonkey software and invitations to
participate were sent by email.
In the first round, panellists were asked to judge whether
each potential core domain was important enough to be
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included in this COS with possible answers ‘yes’, ‘no’ and
‘unsure/not my expertise’. Panellists were given the op-
portunity to propose changes of wording and definitions of
domains, to indicate if some domains had major conceptual
overlap or had to be aggregated, and to suggest the inclu-
sion of missing potential core domains. A question was
asked about the ideal number of domains for this COS and
another about reporting of adverse events (AEs). Panellists
were always encouraged to provide a rationale for their
answers. A priori cut-off criteria were established for ex-
cluding domains that were rejected by more than 60 % and
favoured by less than 20 % of respondents.
In the second round, a proposal was made for exclusion
of domains that did not have at least 67 % of the first round
respondents answering ‘yes’ or ‘unsure/not my expertise’.
Other proposals were made for excluding or retaining do-
mains suggested as having large conceptual overlap.
Consensus for the second round was a priori set at 67 % of
respondents agreeing with a proposal. Panellists were also
asked to judge whether the potential core domains sug-
gested as missing were important enough to be included in
the COS, as done for the other domains in the first round.
The remaining potential core domains were presented in
the third round to ask the panellists if eachwas indeed core.A
priori consensus was set at 67 % of the panel agreeing that a
domain is core. In each round, descriptive statistics were
used to summarize all the questions. All rationales provided
by panellists were checked against the quantitative results to
evaluate whether substantial inconsistencies emerged. Re-
sponses of the patients’ group were always analysed
separately to assess whether discrepancies were emerging
with the rest of the panel. In the third round, frequencies of
responses for each domain were calculated for the whole
panel and separately for each of the stakeholder groups.
Final decisions
The project team made some proposals to the Steering
Committee regarding the interpretation of the final results
of the Delphi. Committee members expressed their opinion
on each proposal and the opinion supported by more than
50 % of members was followed. Some proposals con-
cerned the inclusion of a ‘death’ and a ‘pathophysiological
manifestations’ domain in the COS (as recommended by
the OMERACT initiative for all COSs [19]), and what




We selected a sample of 280 experts to participate: 139
researchers, 108 care providers, 15 patients, and 18 mem-
bers of the Steering Committee. A flowchart of the re-
sponse rate in each round is presented in Fig. 1; 79 of the
selected panellists (29 %) participated in all three rounds.
People from five continents participated, with the United
States, The Netherlands, Australia and the United Kingdom
being the most represented countries (Table 1). Socio-de-
mographic characteristics, panellists’ disciplines of exper-
tise and experience with NSLBP clinical research were not
substantially different between rounds (Table 1). Fourteen
patients (seven men and seven women) participated in the
first round: three had current and past episodes of NSLBP,
six had only a current episode, and three had NSLBP only
in the past. Among the nine with current NSLBP: seven
sought care for their back problem, three were off-work
Selected Participants: N = 280 
Invited Round 1: N = 275 
Responses: N = 143 (52%) 
Invited Round 2: N = 261 
Responses: N = 130 (50%)
Invited Round 3: N = 259 
Responses: N = 117 (45%) 
Drop-outs: N = 11 (4%): 
- 9 unknown reasons  
- 1 ‘leaving academia’ 
- 1 found survey too difficult
5 wrong addresses 
3 wrong addresses 
Drop-outs: N = 1 (0%): 
- 1 ‘could not contribute in 
an independent way’ 
1 wrong address 
Drop-outs: N = 1 (0%): 
- 1 ‘too busy’
Fig. 1 Flowchart of
participation rates per round
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Table 1 Characteristics of participants of the Delphi study
Characteristics Round 1 Round 2 Round 3
Number (n)
Total number of participants 143 130 117
Complete answers on domains 131 127 115
Stakeholder group (%)
Health care researchers 45 44 47
Health care providers 15 15 19
Health care researchers and
providers
30 28 25
Patients 10 8 9
Missing information 0 5 0
Gender (%)
Female 28 24 26
Male 72 74 74
Missing information 0 2 0
Nationality (%)
United States of America 22 21 22
The Netherlands 17 19 20
Australia 11 11 11
United Kingdom 10 12 9
Brazil 6 5 5
Italy 6 5 3
Norway 4 4 2
Canada 3 2 5
Spain 3 3 3
Belgium 2 3 2
Germany 2 2 3
France 1 1 1
Finland 1 1 2
Othera 12 11 12
Work country (%)
United States of America 22 21 23
The Netherlands 17 20 20
Australia 13 11 13
United Kingdom 11 11 9
Brazil 6 5 4
Italy 6 5 3
Norway 4 4 2
Canada 4 3 6
Spain 3 3 3
Belgium 3 2 2
Germany 2 2 3
Denmark 1 2 3
France 1 2 1
Finland 1 1 2
Switzerland 1 1 0
Othera 5 7 6
Educational backgroundb (%)
Physiotherapy 36 32 34
Table 1 continued
Characteristics Round 1 Round 2 Round 3
Epidemiology 28 26 29
Orthopaedics 12 12 14
Rheumatology 8 9 7
Human movement science 8 8 10
Internal medicine 7 8 8




Anesthesiology 5 4 3
Chiropractic 4 4 5
Osteopathy 4 2 3
Neurosurgery 3 2 2
Other 17 18 21
Missing information 0 5 0
Field of workb (%)
Physiotherapy 32 29 30
Epidemiology 29 28 30
Orthopaedics 22 23 19




Anesthesiology 4 6 5
Psychology 6 5 5
Chiropractic 4 4 1
Human movement science 4 5 3
Internal medicine 2 3 1
Neurosurgery 4 3 3
Osteopathy 4 3 1
Other 47 22 29
Missing information 0 5 0
Clinical trials in NSLBPc (%)
None 19 19 17
1–3 clinical trials 36 37 41
[4 clinical trials 45 37 42
Missing information 0 7 0
Systematic reviews in NSLBPc (%)
None 42 44 31
1–3 systematic reviews 39 33 43
[4 systematic reviews 19 16 26
Missing information 0 7 0
Development of measurement instruments for NSLBPc (%)
None 48 44 48
1 measurement instrument 26 25 18
[2 measurement instruments 26 24 34
Missing information 0 7 0
Testing of measurement instruments for NSLBPc (%)
None 32 28 31
1–3 studies 47 44 46
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due to their LBP, two had acute NSLBP (i.e. pain for less
than a month), three chronic NSLBP from three months to
a year, four chronic NSLBP for more than a year. None of
the patients underwent a surgical operation for current and/
or past episodes of LBP. In total, forty-six panellists of the
first round (32 %) sought care for a present or past episode
of LBP but only those specifically invited as patients were
considered part of this stakeholder group.
List of potential core domains
The list of potential core domains generated by the Steering
Committee included 41 outcome domains, subdivided as
follows: 1 in the core area ‘death’, 21 in ‘life impact’, 6 in
‘resource use/economical impact’ and 13 in ‘pathophysio-
logical manifestations’. The list with all definitions used in
the Delphi study is presented in Table 2.
Delphi round 1
The first round ran from February 18 to March 24, 2014.
The results on inclusion of the 41 domains are presented in
Fig. 2. Six domains met a priori criteria for exclusion:
‘legal services’, ‘body structures’, ‘muscle tone’, ‘struc-
tural stability’, ‘proprioception’ and ‘urination’. For 12 of
the other domains, at least 67 % of respondents indicated
that they should be included in the COS or were unsure
about it (Fig. 2). The remaining 23 domains did not reach
this threshold and their exclusion was proposed in the
second round. No clear discrepancies between the patients’
perspective and overall panel responses were identified.
One hundred and thirty-one panellists answered the
question on the ideal number of domains and 106 (81 %)
indicated a specific number; the suggested median number
of domains was 7 (interquartile range 5–10) and the ma-
jority of the comments were in favour of a small COS. The
majority of respondents to the question on AEs (72 %)
agreed that only AEs occurring outside of core outcome
domains should be reported as AEs.
Several panellists emphasized the overlap of ‘health-
related quality of life’ with other more specific domains
(e.g. ‘physical functioning’, ‘psychological functioning’)
(see ‘‘Appendix II’’). To address this, a proposal was
formulated for the second round to exclude ‘health-related
quality of life’ from the list. Panellists also remarked that
‘work ability’ and ‘work productivity’ should not be in-
cluded in all trials because they are not applicable to non-
working populations, and because they overlap (‘‘Ap-
pendix II’’). These comments had to be balanced against
favourable comments for inclusion and prompted a pro-
posal for the second round to retain these two domains in
the list with an adapted definition that includes also non-
paid workers (e.g. students, housewives). Several panel-
lists commented about the overlap of ‘pain interference’
with other domains (‘‘Appendix II’’) and these comments
were addressed in a proposal to retain it in the list despite
the overlap. Despite disagreements on inclusion of ‘non-
health care services’ (Fig. 2), substantial arguments were
put forward in its favour. Two patients emphasized that
these services (e.g. alternative health care) can be very
important, others highlighted that what constitutes ‘non-
health care services’ can differ between countries and that
they can be relevant cost-drivers (‘‘Appendix II’’). Based
on these comments, a proposal for the second round was
made to incorporate the content of this domain into
‘health care services’. In total, 16 new potential core
domains were suggested by panellists for inclusion in the
list. Appropriate definitions were searched for these do-
mains and they were presented in the second round for
rating (‘‘Appendix III’’).
Delphi round 2
The second round ran from April 27 to May 26, 2014.
Consensus was reached for the exclusion of all but one
domain (i.e. ‘social functioning’, 64 % consensus) that did
not have at least 67 % support from the first round. No
substantial arguments favoured the retention of these
domains.
Consensus was not obtained for excluding the domain
‘health-related quality of life’ (55 % of the panel recom-
mended its exclusion). Some substantial arguments (e.g.
‘‘Construct overlap can only be answered empirically. It is
just as likely that the entire question set loads on a single
factor, or that there are a few higher order factors. Pain,
pain interference, physical functioning, QOL, work, sleep,
self-rated health have all been showing to share variance in
previous studies. […].’’) explained the lack of consensus.
Consensus was obtained (i.e. 85 %) for incorporating
Table 1 continued
Characteristics Round 1 Round 2 Round 3
[4 studies 21 21 23
Missing information 0 7 0
COS developmentc (%)
None 70 63 65
[1 COS 30 30 35
Missing information 0 7 0
a Participants with more than one nationality or working in more than
one country are included in this category
b Percentages are calculated on the whole sample because each
participant could indicate more than one field
c Participation in the design, analysis and/or conduction of the
mentioned type of study. These questions were not asked to patients,
percentages are calculated on the sample of potential respondents
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Table 2 Definitions of potential core domains considered for NSLBP clinical trials
Core area Domain Definition
Death Number of deaths Reporting of number of deaths occurred within a clinical trial
Life impact Health-related quality of
life
Impact on physical, psychological and social domains of health, seen as distinct areas that
are influenced by a person’s experiences, beliefs, expectations and perceptions
Life impact Illness perception Impact on cognitive and emotional representations of the illness that patients develop to
respond to a perceived health threat and that will give rise to problem-based and
emotion-focused coping procedures
Life impact Work ability Impact on a worker ability to meet physical and/or psychological work demands
Life impact Individual work
performance
Impact on work behaviours or actions that are relevant to the goals of the organization
Life impact Physical functioning Impact on patient’s ability to carry out daily physical activities required to meet basic
needs, ranging from self-care to more complex activities that require a combination of
skills
Life impact Psychological functioning Impact on patient’s levels of anxiety, depression, anger, or other types of psychological
distress. Anxiety refers to fear, extreme worrying and hyperarousal symptoms.
Depression refers to negative mood, loss of self-confidence, loss of motivation and
enjoyment. Anger refers to irritability and frustration
Life impact Cognitive functioning Impact on patient’s levels of attention, memory, concentration and perception. Attention
refers to the ability to focus on tasks, memory refers to the ability to recall information,
concentration to the ability to sustain attention, and perception to the ability to interpret
information
Life impact Social functioning Impact on patient’s ability to interact with people in a contextually and socially appropriate
manner (e.g. showing consideration and esteem when appropriate, responding to the
feeling of others), to create and maintain close relationships with others (excluding
members of the family), to engage in desired aspects of community social life (e.g.
charitable organizations, service clubs or professional social organizations)
Life impact Sexual functioning Impact on patient’s ability to conduct physical and mental functions related to intimacy
and sexual acts
Life impact Recreation and leisure
activity
Impact on patient’s ability to engage in any form of play, recreational or leisure activity
Life impact Satisfaction with social
roles and activities
Impact on patient’s satisfaction in performing usual social roles and activities (including
family and work)
Life impact Satisfaction with treatment
services
Impact on patient’s satisfaction with care received, including treatment and care providers
Life impact Sleep functioning Impact on sleep functions like onset, maintenance, quality, amount of sleep, and functions
involving the sleep cycle. This domain should also include the impact on perceptions of
alertness and sleepiness during usual waking hours
Life impact Fatigue Impact on fatigue, ranging from mild subjective feelings of tiredness to an overwhelming,
debilitating, and sustained sense of exhaustion that it is likely to decrease one’s ability to
carry out daily activities (including work activities) and to function at one’s usual levels
in family or social roles
Life impact Pain intensity Impact on how much a patient hurts, reflecting the overall magnitude of the pain
experience
Life impact Pain quality Impact on sensory and affective qualities of the pain a patient experiences
Life impact Temporal aspects of pain Impact on variability of pain over time, namely frequency and duration of pain episodes
Life impact Pain behaviour Impact on external manifestations of experiencing pain, such as verbal or nonverbal,
involuntary or deliberate actions and reactions
Life impact Self-rated health Impact on the subjective rating of patients regarding their general health perceptions,
including all the existing health concepts
Life impact Pain interference Impact on consequences of pain on relevant aspects of a patient’s life and may include the
impact of pain on social, cognitive, emotional, physical and recreational activities
Life impact Independence Impact on ability to get things the patient wants to do, without the help of others
Resource use/
economical impact
Work productivity Economical impact on paid or unpaid job employment due to low back pain, including
absenteeism and presenteeism
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‘‘non-health care services’’ into ‘‘health care services’’, for
retaining ‘work ability’ and ‘work productivity’ as inde-
pendent domains (72 %), and for retaining ‘pain interfer-
ence’ in the list (68 %).
However, relevant arguments were made against in-
cluding ‘health care services’ and ‘work productivity’ in
the list of potential core domains. These arguments out-
lined that, given the scope of the COS, it might not be
appropriate to include these domains in efficacy trials (e.g.
‘‘[…] Often in trials patients are requested not to under-
take/receive any other treatments during the intervention
period, which means differences in use depend on things
other than the patient’s health state […]’’). Several panel-
lists also questioned whether there are valid and reliable
methods to assess these domains in all clinical trials (e.g.
‘‘[…] during follow-up the acquisition of accurate and
Table 2 continued
Core area Domain Definition
Resource use/
economical impact
Health care services Utilization of health care services within the formal health care system for treating low
back pain, including: visits for primary and secondary care, laboratory tests, days of
admission to a hospital, medications
Resource use/
economical impact




Non-health care services Utilization of health care services not included in the formal health care system for treating
low back pain, including: visits to professionals of alternative medicine, ‘‘over-the-
counter’’ medications, patients’ time and travel expenses
Resource use/
economical impact
Societal services Utilization of public services, systems or policies aimed at providing support to people
who require assistance that is funded by general tax revenues or contributory schemes
Resource use/
economical impact








Body structures Bones, joints, muscles, tendons, nerves and other body structures localized on the lumbar




Muscle strength Force generated by the contraction of a muscle or of a group of muscles of the lumbar




Range of motion Quantity of movement of the lumbar spine and/or of other adjacent body parts (i.e. thoracic
spine, pelvis, rib cage or lower limbs)
Pathophysiological
manifestations
Muscle endurance Capability of sustaining contractions for a required period of time of a muscle or of a group
of muscles of the lumbar spine and/or of other adjacent body parts (i.e. thoracic spine,
pelvis, rib cage or lower limbs)
Pathophysiological
manifestations
Muscle tone Tension present in the resting muscles (i.e. resistance offered when trying to move them
passively) of the lumbar spine and/or of other adjacent body parts (i.e. thoracic spine,
pelvis, rib cage or lower limbs)
Pathophysiological
manifestations








Spinal control Capability of performing all aspects related to the control of movement (i.e. motivation to
move, sensory inputs, integration of inputs and planning of outputs, motor output to the
muscles and mechanical properties of the tissues of the lumbar spine) of the lumbar spine
and/or other adjacent body parts
Pathophysiological
manifestations
Physical endurance Respiratory and cardiovascular capacity for enduring physical exercise
Pathophysiological
manifestations
Urination Capability of discharging the urinary bladder
Pathophysiological
manifestations
Gait Movement patterns associated with walking, running or other whole body movements
Pathophysiological
manifestations
Neurological signs Impairments of nerves, spinal cord or brain functions that affect a specific region of the
body
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reliable health care services data is questionable’’, or ‘‘[…]
both are difficult to assess, may be influenced by factors
other than the presence of LBP, and I am not sure of the
reliability of the assessment methods’’). These domains
were kept in the list but these arguments were highlighted
in the third round.
None of the new potential core domains suggested in the
first round reached consensus for inclusion. Votes for in-
clusion ranged from 60 % for ‘satisfaction with the out-
come of treatment’ to 13 % for ‘travel and transportation’.
No substantial differences between patients’ responses and
the rest of the panel emerged. A total of 13 domains were
retained in the list of potential core domains and presented
in the last round.
Delphi round 3
The third round ran from June 23 to July 17, 2014. Three
domains exceeded the a priori threshold for inclusion in the
COS: ‘physical functioning’ (96 % of respondents indi-
cating it as core), ‘pain intensity’ (90 %) and ‘health-re-
lated quality of life’ (73 %) (Fig. 3). These ratings were
consistent across stakeholder subgroups with the only ex-
ception that the patients’ group that did not reach agree-
ment (55 %) on ‘health-related quality of life’ (Fig. 3).
‘Work ability’ was rated as a core domain by 76 % of
health care providers but only by 64 % of the whole panel
and 36 % of the patients (Fig. 3). ‘Psychological func-
tioning’ was considered a core domain by 76 % of care
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providers and 91 % of patients but not by the whole panel
(Fig. 3). While providers and patients provided ten com-
ments in favour of its inclusion, half of these supported its
inclusion as a confounder or moderator, being these not
appropriate arguments to support inclusion as an outcome
domain. The other eight potential core domains did not
reach consensus for inclusion in the COS for any stake-
holder group, except 82 % of the patients that rated ‘self-
rated health’ as a core domain (Fig. 3).
Final decisions
Based on the Delphi results, the majority of the Steering
Committee members agreed on including ‘physical func-
tioning’, ‘pain intensity’ and ‘health-related quality of life’ in
this COS. The Steering Committee considered the inclusion
of ‘health-related quality of life’ because there were strong
arguments in its favour: overall consensus was reached, three
groups of stakeholders were in favour, and its definition
(Table 2) incorporated the excluded domains ‘psychological
functioning’ and ‘self-rated health’ that were rated as core by
some groups of stakeholders (Fig. 3). The Steering Com-
mittee also agreed on the exclusion of ‘work ability’ as overall
agreement for inclusion was not reached, as several argu-
ments for inclusion were weak and as it was not considered
core by three groups of stakeholders (Fig. 3). These decisions
were also taken with the intention of keeping this COS as
short as possible to facilitate its implementation.
The majority of Steering Committee members agreed on
including the domain ‘number of deaths’ in the COS as this
emphasizes the need to report on the occurrence of deaths in
every clinical trial. The Steering Committee acknowledges
that death is a rare event for NSLBP clinical trials but a
short statement, such as ‘‘no deaths occurred in this clinical
trial’’, would suffice to cover this outcome domain. The
Steering Committee did not agree with the inclusion of a
generic pathophysiological manifestation domain in this
COS, as recommended by OMERACT [19]. The main ra-
tionale for this decision was that not all interventions for
NSLBP are targeting a pathophysiological manifestation, as
this disorder is characterized by the absence of a known
pathophysiology [6–8, 25]. Furthermore, its inclusion could
create unnecessary increases in research costs and impact
upon the brevity of the COS. This recommendation does not
imply that measuring pathophysiological manifestations is
unimportant in relevant NSLBP clinical trials and re-
searchers are encouraged to include them when appropriate
for their individual studies.
In the first round of the Delphi, consensus was reached on
the reporting of AEs only for those domains not already
included in the COS. This approach ensures that, where
appropriate, AEs that occur within a core outcome domain
(e.g. an increase in ‘pain intensity’ or a decrease in ‘health
related quality of life’) are included in the statistical analy-
sis. However, taking into account some comments by Delphi
panellists, the Steering Committee decided to adopt a flex-
ible approach to the reporting of AEs. This approach leaves
the option open to trialists to also report, as separate AEs,
those negative outcomes occurring within core domains.
Discussion
Using the methodological guidance of initiatives like
COMET and OMERACT [16, 19], we performed a Delphi
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multistakeholder consensus-based update of an earlier
standardized set of outcome domains for LBP research [20,
21]. Sufficient agreement was reached on core outcome
domains that are part of a COS intended for clinical trials
assessing efficacy or effectiveness of health interventions
in patients with NSLBP. The domains included in this COS
are ‘physical functioning’, ‘pain intensity’, ‘health-related
quality of life’ and ‘number of deaths’ (see definitions in
Table 2).
The domain ‘physical functioning’ reached the highest
level of consensus in this study and the definition focuses
on ability to engage in daily physical activities (Table 2).
Our definition of ‘physical functioning’ will be funda-
mental to determine which measurement instrument would
best measure this domain. IMMPACT recommendations
for chronic pain clinical trials also suggest measuring
‘physical functioning’ as a core outcome domain [40, 41],
and this convergence strengthens its inclusion.
‘Pain intensity’ also reached a very high level of con-
sensus for inclusion in this COS. The inclusion of a pain
domain is in line with the original core set [20, 21] and
IMMPACT recommendations [40, 41]. ‘Pain intensity’ for
this COS refers to the magnitude of the pain experience,
whereas other pain (sub)domains were suggested for con-
sideration by the previous core set and/or IMMPACT (e.g.
‘bothersomeness of pain’, ‘pain quality’, ‘temporal aspects
of domains’, ‘pain medications’) [20, 21, 40, 41]. Some of
those pain domains and others (i.e. ‘Pain behaviour’, ‘pain
interference’) were presented as potential core domains in
this Delphi but not sufficient agreement was reached to
consider them as core (Figs. 2, 3).
‘Health-related quality of life’ included in this COS
could be considered as the ‘successor’ of ‘general well-
being’ included in the previous set [20, 21]. However, a
definition of ‘general well-being’ was not given for the
previous set and this makes a clear comparison of the two
constructs challenging. Taking into account the widely
accepted bio-psycho-social model for LBP [42, 43], it may
be appropriate to have a domain like ‘health-related quality
of life’ in this COS as its definition includes all components
of the model (Table 2). The inclusion of all components of
the bio-psycho-social model is also in line with the do-
mains included in a conceptual framework developed to
characterize the burden of LBP [35] and with the results of
a review that attempted to summarize qualitative research
conducted on the impact of LBP on people’s lives [44].
However, it will be clear only when choosing measurement
instruments for this COS if the different components of
‘health-related quality of life’ can be treated as separate
domains or as one multidimensional domain. The choice of
instruments will also be guided by the intention of
minimizing redundancy of measurement, to avoid large
overlap of instruments and promote brevity of the COS.
Another key aspect in the development of a COS is the
definition of contextual factors (i.e. potential confounders
and effect modifiers) that should be measured alongside
core outcome domains [19]. However, it was beyond the
scope of this study to address contextual factors and for the
measurement of these factors a reference is made to the
prominent work of the National Institutes of Health (NIH)
Task Force [45]. This Task Force recently published a re-
port on minimum baseline standards that should be col-
lected in clinical studies for chronic LBP, to standardize
their assessment [45].
This COS includes refined versions of three domains
included in the previous standardized set but does not in-
corporate the other two: ‘disability social role’ and ‘satis-
faction with care’ [20, 21]. ‘Disability social role’ referred
to work absenteeism and could be replaced by the domain
‘work productivity’ used in this study, while ‘satisfaction
with care’ was formulated as ‘satisfaction with treatment
services’ in this study, but neither was supported by the
Delphi panel (Figs. 2, 3). ‘Work productivity’ refers to
indirect non-medical costs that are the first cost drivers for
LBP [5] and it is an undoubtedly important outcome for
clinical trials with economic evaluations alongside. How-
ever, this domain poses the challenge of its measurement in
clinical trials aimed at assessing efficacy of interventions,
in which an economic evaluation might be out of the scope
of the trial. To support the exclusion of ‘satisfaction with
treatment services’ several panellists underlined that it
could be highly influenced by factors unrelated to an in-
tervention (e.g. waiting list, amiability of providers, un-
friendly receptionist, parking difficulty) and, consequently,
that it could say relatively little about efficacy or effec-
tiveness of that intervention.
This is the first Delphi study conducted to explore in-
ternational, multistakeholder, and multidisciplinary con-
sensus on core outcome domains to be reported in NSLBP
clinical trials. This study highlighted diverging opinions on
the importance of some domains and reinforced the wis-
dom of a comprehensive exercise to determine which
outcome domains are felt by the majority to be core. The
strengths of this study include methods that followed
guidance of initiatives like COMET and OMERACT [16,
19], having a large expert panel of varied stakeholders
representing various disciplines and countries, giving the
opportunity to Delphi panellists to provide comments for
each choice, allowing panellists to reconsider their views
after considering other panellists’ reasoning, attempting to
address strong arguments emerging from the Delphi panel,
and rigorous reporting of methods [26] and results. One
limitation of this study could be the relatively small
number of patients involved in the Delphi rounds, which
could have led to under or overestimation of the impor-
tance of certain domains from their perspective. However,
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the goal of this study was not to develop a comprehensive
range of outcome domains important to all stakeholders,
but rather a core set for inclusion in all clinical trials. Pa-
tients can also be involved in trial management teams
where they can shape the range of outcomes measures
collected in individual trials and this should represent good
practice. Finally, the definition of COSs places emphasis
on the concept of a minimum set [16, 19] and the four
domains included in this COS seem to fit perfectly within
this definition. The existence of a small COS for NSLBP
should facilitate its inclusion in clinical trials, alongside
trial-specific outcomes.
The development of a COS is a stepwise approach
[16, 19] and this study determined core outcome do-
mains for clinical trials on NSLBP. The next step will be
to reach consensus on which measurement instruments
should be used to measure these outcome domains. The
selection of instruments will be focused on those that
have demonstrated adequate measurement properties for
these domains with the least participant burden. Recently
published methodological guidance on this topic [46, 47]
will help to conduct the next step for this COS in
NSLBP.
Conclusions
A consensus-based COS for NSLBP was developed and
included the domains ‘physical functioning’, ‘pain inten-
sity’, ‘health-related quality of life’ and ‘number of
deaths’. This COS represents the update of the standardized
set proposed by Deyo et al. in 1998 [20, 21]. The brevity of
this COS should facilitate its implementation in clinical
trials assessing efficacy or effectiveness of health inter-
ventions for NSLBP. Future research should establish
which measurement instruments are the most appropriate
to measure these core outcome domains.
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Table 3 OMERACT Filter 2.0 framework specifying all aspects of a health condition that should be considered in clinical trials (adapted from
Boers et al. [19])
Core area Specification
Deatha This core area includes possible specifications of death, as generic or disease-specific, i.e. all cause vs disease-
specific morality; and intervention-specific (e.g. death due to surgery)
Life impacta This core area can include domains of the ICF (3) (e.g. activity and participation) and domains within the concept
of health-related quality of life (14) (e.g. functional status, general health perceptions, overall quality of life)
Resource use/economical
impacta
This core area describes the economical impact of health conditions both on society and on the individual. In fact,
the presence of a health condition and its treatment incur resource use
Pathophysiological
manifestationsb
This core area is to assess whether or not the effect of the intervention specifically targets the pathophysiology of
the health condition. Pathophysiology can include psychosocial manifestations. Example domains are: ICF body
function, reversible manifestations (including modifiable risk factors and actual manifestations of ill health), and
irreversible manifestations (including unmodifiable risk factors and damage). This area can also encompass all
biomarkers and surrogate outcomes
a These core areas belong to the concept ‘impact of health conditions’ that includes all aspects of health or a health condition that are important
to the patient and society
b This core area belong to the concept ‘pathophysiological manifestations of health conditions’
Table 4 Relevant comments regarding some domains with good level of consensus in the first round
Domain Comments inconsistent with the overall group response
Health-related
quality of life
‘‘Overlaps with other domains listed in this core area’’
‘‘Too broad domain’’
‘‘Too generic’’
‘‘Conceptual and measurement overlap with other core variables above and list below’’
‘‘Too broad’’
‘‘This is the overarching domain with other encompasses many of the previous domains discussed’’
‘‘Strongly agree that HR-QoL is a critical domain to include in the COS. It encompasses relevant aspects of
psychological, physical and social functioning that patient’s identify as key domains for their recovery from LBP (1). If
this is included, then there is no need to include items 22, 27 and 33 as they become redundant’’
‘‘Would be a way to capture important aspects of many of the preceding domains’’
‘‘This may be duplicating other measures of mood, social, pain, and function. There is also a cost associated with these
with licensees’’
‘‘This is an important one, but seems it would fit within other domains’’
‘‘For me, this would depend on the exact measure, and how much it overlaps with other domains’’
‘‘This is vague, or maybe too broad’’
‘‘Health-related QOL has substantial overlap, as stated in its definition, with the components listed elsewhere of physical,
psychological and social functioning’’
‘‘Quality of life is unnecessary given all the other measures’’
‘‘In my mind, HRQoL overlaps with all the other domains’’
‘‘Many of the items overlap by example HRQL and self-rated’’
‘‘HR QOL picks up a lot of aspects of these domains–for trials and getting them done it might be preferred for efficiency
reasons’’
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Table 4 continued




‘‘Not all subjects are working’’
‘‘Work is not relevant to ALL patients with LBP (some are retired, some are sick listed / on long-term sick and disability
benefits, some are students etc). Whilst work ability is a key outcome for the working population with LBP, it seems
unreasonable to include it in a COS. Interference with life and physical functioning should ‘cover’ this domain, as for
those who are working, their work takes up a lot of their time’’
‘‘Too much overlap with work productivity (this could replace it though)’’
‘‘Work ability seems to overlap with absenteeism and presenteeism’’
‘‘Work ability could be combined with presenteeism in the prior list of factors’’
‘‘Work ability is important for most people, but should perhaps be extended to include other activities for people who do
not have a job’’
‘‘Actual work is the bottom line success in this area, however economic factors may vary, causing undue variation in
study outcomes from time to time and location to location. Also the person’s interest in work may vary. They may have
children, retire, or the episode may help them realize that they need to go to school or do something else in life. So
measuring the ability is definitely second in importance to actual work success. But it can be useful’’
‘‘Yes but unsure if work ability should be within productivity and health QOL. Needs very strict description of what is
ability and outcome is more related to whether do or do not participate rather than ability to participate in work/
activity’’
‘‘Work ability could be relevant from the patient’s perspective–but may not be applicable to everyone (eg those that do
not work etc)’’
‘‘Work productivity should be given very high priority. The problem with this domain comes with handling people who
are not in the labor force (students, retired persons, homemakers), it would be helpful if there were clear guidance on
how work outcomes are handled when not all of the sample is in the labor force. This contingency can create difficulties
in reporting trial results’’
‘‘Work productivity is very important but should also encompass not just work as many unemployed and more and more
retired as population ages. Why not just productivity related to all paid or unpaid activity and include ADLs’’
Pain interference ‘‘Work ability should be covered by pain interference’’
‘‘Psychological functioning covers the important impact of pain on patient life, it overlaps with pain interference’’
‘‘Recreation and leisure would be captured under the HRQOL and pain interference’’
‘‘Pain interference is covered by physical functioning’’
‘‘Would fold pain interference into functional restoration and/or psychosocial domains’’
‘‘Pain interference is too broad, captures a number of the other domains’’
‘‘Pain interference covers a broad range of constructs (disability, depression, social participation, to name a few) and so
interpretation may not be straightforward’’
‘‘I think that pain interference overlaps with physical functioning and HRQoL domains’’
‘‘In a way this can overlap with physical functioning, i.e. physical functioning might be impaired partly because of ‘pain
interference’’’
‘‘This would be a good one to combine others into–social functioning, recreational functioning etc’’
‘‘Can pain inference be separated from other variables?’’
‘‘Obviously this is very important, not sure that it is core, depends on the other domains chosen and their
interrelationship’’
‘‘Physical functioning and pain interference overlap’’
Non-health care
services
‘‘Absolutely. Much of low back care occurs outside of the formal healthcare system. Patients, for instance, often engage
in both mainstream and alt/comp medicine. And since most back is coping issue rather than a ‘treat and cure’ disease,
it is important to understand the full array of services patients utilize. Think this question should be reworded. The types
of services mentioned are all healthcare services so shouldn’t be termed ‘‘‘‘non-healthcare services’’
‘‘Non-health care services are commonly used by patients with LBP. They are often quite expensive’’
‘‘Non-health care services are used by the vast majority of back pain patients’’
‘‘This category will vary substantially between cultures/regions, but informal services can represent a significant fraction
of HC services sought by patients with LBP. Could be a very brief question/assessment (# visits)’’
‘‘Alternative therapy is fundamental for a better life style, especially when the patient requires non official cures,
recognized by protocols, for example patients with allergies to medicines’’
In italics are presented those comments that were made by patients
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Appendix III
Missing potential core domains suggested
by panellists in the first round
1. Decision quality = shared decision making that fo-
cuses on two areas: (1) the extent to which patients
are informed about treatment options, and (2) the
extent to which treatments match what is most im-
portant to patients.
2. Satisfaction with the outcome of treatment = extent
to which the patient is satisfied with the results of
treatment.
3. Abuse/misuse of drugs = misuse or abuse of
prescribed or not prescribed drugs.
4. Pain self-efficacy = degree of confidence a patient
has in performing regular activities despite the
presence of pain.
5. Pain catastrophizing = tendency to misinterpret and/
or exaggerate actual or anticipated pain experiences.
6. Bodily extent of pain = number of painful body areas
besides the pain experienced in the back.
7. Size of painful area = dimension of the body area in
which the patient experiences pain.
8. Compliance with treatment = degree to which a
patient follows treatment in all its components.
9. Coping = purposeful use of cognitive and behavioral
techniques to manage demands that are perceived as
stressful or taxing the resources of the individual.
10. Patient nominated goals = subjective judgment about
the achievement of pre-set individual goals.
11. Participation = involvement in a life situation.
12. Recovery = an individual’s determination of his/her
recovery which involves cognitive appraisal of the
impact of symptoms on his/her life, the capacity to
perform relevant daily activities, and achievement of
an acceptable quality of life through readjustment
and other adaptive strategies.
13. Acceptance of pain = willingness to have uncom-
fortable experiences when the actions that bring
about those experiences serve important purposes for
the individual.
14. Kinesiophobia = excessive, irrational, and debilitat-
ing fear of physical movement and activity resulting
from a feeling of vulnerability to painful injury or
reinjury.
15. Patient impression of change = patient’s assessment
of the change related to low back pain since
beginning of treatment.
16. Travel and transportation = patient’s difficulty with
travel and transportation.
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